Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from Rheumatoid arthritis patients

Serum Interleukin-15 Levels Are Associated with Severity of Pain in Patients with Knee Osteoarthritis

(2013) Jian-Min Sun et al.   DISEASE MARKERS

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

(2013) Yves-Marie Pers et al.   RHEUMATOLOGY

Circulating IL-15 exists as heterodimeric complex with soluble IL-15R  in human and mouse serum

(2012) C. Bergamaschi et al.   BLOOD

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

(2012) Iris Navarro-Millán et al.   CLINICAL THERAPEUTICS

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Role of proinflammatory cytokines in the pathophysiology of osteoarthritis

(2010) Mohit Kapoor et al.   Nature Reviews Rheumatology

Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease

(2009) C.R. Scanzello et al.   OSTEOARTHRITIS AND CARTILAGE

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

(2009) Andrea Rubbert-Roth et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin-15 stimulates macrophages to activate CD4+T cells: a role in the pathogenesis of rheumatoid arthritis?

(2008) René Rückert et al.   IMMUNOLOGY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)

(2008) M. H. Buch et al.   RHEUMATOLOGY

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor   expression in the synovium

(2007) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES